Multivariate analysis
| Positive features . | MCyR . | EFS . | OS . | |||
|---|---|---|---|---|---|---|
| Odds ratio . | P . | Hazard ratio . | P . | Hazard ratio . | P . | |
| Chronic phase | 0.29 | < .001 | 2.2 | < .001 | 4.2 | < .001 |
| No or low IC50 mutation | 0.18 | .003 | 2.1 | .002 | 1.8 | .06 |
| Previous MCyR to imatinib | 7.5 | < .001 | 0.56 | .006 | 0.56 | .04 |
| Positive features . | MCyR . | EFS . | OS . | |||
|---|---|---|---|---|---|---|
| Odds ratio . | P . | Hazard ratio . | P . | Hazard ratio . | P . | |
| Chronic phase | 0.29 | < .001 | 2.2 | < .001 | 4.2 | < .001 |
| No or low IC50 mutation | 0.18 | .003 | 2.1 | .002 | 1.8 | .06 |
| Previous MCyR to imatinib | 7.5 | < .001 | 0.56 | .006 | 0.56 | .04 |